Overview

Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Collaborator:
Novartis
Treatments:
Ciprofloxacin
Criteria
Inclusion Criteria:

- Patients with a proven and documented diagnosis of non-cystic fibrosis idiopathic or
post pneumonic bronchiectasis

- Stable pulmonary status and stable regimen of standard treatment at least for the past
30 days

Exclusion Criteria:

- Forced Expiratory Volume 1 < 35% or > 80%

- Allergic bronchopulmonary aspergillosis

- Immunodeficiency disease requiring immunoglobulin replacement

- Inflammatory bowel disease